GHK-Cu: what the research actually shows, and doesn't

Last updated 2026-07-24

What is GHK-Cu and why do people call it a copper peptide?

GHK-Cu is a naturally occurring tripeptide, glycyl-L-histidyl-L-lysine, bound to a copper ion. It shows up in human plasma, saliva, and urine, and its levels drop as people age, which is part of why it got tagged as an anti-aging molecule decades ago. The "copper peptide" name is literal: the peptide chelates Cu(2+) and that copper is what drives most of its biological activity, since copper is a cofactor for enzymes involved in collagen crosslinking and antioxidant defense. A 2018 review in the International Journal of Molecular Sciences ties GHK-Cu's effects to broad gene expression changes, describing it as influencing gene networks involved in tissue repair, protection against oxidative stress, and inflammation control ^[1]. That's a mechanistic, gene-expression level claim, not a clinical outcome claim. It's the kind of finding that explains why researchers keep studying the molecule, but it doesn't by itself tell you what a cream or an injection will do to a person's skin or joint. Worth saying plainly: "GHK-Cu" as a lab reagent, a cosmetic ingredient in a serum, and a compounded injectable are three different physical products even though the peptide-copper complex is the same core chemistry. Purity, concentration, delivery vehicle, and route change the outcome. None of that is optional detail; it's the whole story of why the literature looks so scattered.

What does the actual skin and wound-healing evidence show?

This is where GHK-Cu has its deepest literature, and it is a real strength compared to most trending peptides. But the depth is mostly cell culture and animal models, with a thinner layer of small human cosmetic studies on top. In mice, GHK-Cu loaded into liposomes sped up healing of scald burns, with the treated group showing more cell proliferation and new blood vessel formation (angiogenesis) in the wound bed compared to controls, according to a 2017 study in Wound Repair and Regeneration ^[2]. A 2025 hydrogel study using a food-derived tripeptide-copper complex found improved healing in infected wound models in Biomaterials Research ^[3]. Separately, a 2025 study built an injectable hydroxyapatite microsphere filler loaded with GHK-Cu and reported anti-inflammatory and antioxidant effects in that delivery system, published in Colloids and Surfaces B ^[4]. On the human cosmetic side, a 2025 review in BioImpacts examined topically applied GHK as an anti-wrinkle ingredient and discussed both its advantages and its practical problems, including formulation stability and how much actually gets into skin ^[5]. A 2023 fibroblast and ex-vivo skin study found that GHK-Cu combined with hyaluronic acid upregulated collagen IV production, a component of the skin's basement membrane, in the Journal of Cosmetic Dermatology ^[6]. So: strong mechanistic and animal-model support for wound repair, a genuinely interesting collagen signaling story in human skin cells and ex-vivo tissue, and a much thinner record of controlled trials in living human volunteers measuring actual wrinkle depth or clinical wound closure over time. If someone tells you GHK-Cu is "clinically proven" to reduce wrinkles in humans, ask which trial, on how many people, for how long. The honest answer right now is: not many, and not large.

Does GHK-Cu actually penetrate the skin from a topical product?

This is the question most serum marketing skips, and it matters enormously. GHK-Cu is a charged, water-soluble tripeptide-copper complex, not a small lipophilic molecule, so getting it through the stratum corneum in meaningful amounts is a real formulation problem, not a given. A 2025 study in Molecules directly asked whether researchers are even equipped to measure skin permeation of GHK-Cu when it's encapsulated in liposomes, which tells you the measurement science itself is still being worked out ^[7]. A related 2023 paper in Pharmaceutics on liposomes as carriers for GHK-Cu in cosmetic use found that encapsulation is one practical strategy to improve delivery into skin ^[8], and a 2024 Electrophoresis paper used capillary electrophoresis-ICP-MS/MS to monitor how much GHK-Cu cosmetic ingredient actually ends up encapsulated in liposomes versus free in the formula ^[9]. The practical takeaway: plain aqueous GHK-Cu serums face a real penetration barrier, liposomal encapsulation is an active area of formulation research aimed at solving that, and the fact that multiple 2023 to 2025 papers are still trying to nail down measurement methods tells you this isn't a solved problem industry-wide. A product that just lists "copper tripeptide-1" on the label without any delivery technology is leaning on the ingredient's reputation more than on demonstrated skin penetration data.

Topical GHK-Cu vs injectable GHK-Cu: how different are they really?

Very different, and conflating them is the single most common mistake in how this peptide gets marketed. Topical GHK-Cu is a cosmetic-route product. It has to survive being rubbed onto skin, cross the stratum corneum (a real barrier problem, see above), and act mostly on epidermal and upper dermal cells. The wrinkle and collagen literature cited above ^[5][6] is almost entirely topical or ex-vivo skin model work. Injectable GHK-Cu, whether subcutaneous or intradermal, bypasses the skin barrier entirely and delivers the peptide-copper complex directly into tissue. That changes the pharmacokinetics completely: systemic absorption is possible, local tissue concentration is far higher, and the safety profile is a different question. A 2026 primer in The American Journal of Sports Medicine on injectable peptide therapy for orthopaedic and sports medicine physicians treats this class of compounds as a distinct clinical category with its own risk and evidence considerations, separate from topical cosmetic use ^[10]. A companion 2026 review in JAAOS Global Research & Reviews covers therapeutic peptides in orthopaedics broadly, including the practical and regulatory challenges of using compounded injectable peptides in that setting ^[11]. The animal data most relevant to injectable use in joints comes from a 2015 rat study in the Journal of Orthopaedic Research, where a GHK-Cu(II) complex was tested in an ACL reconstruction model and produced a healing benefit described as transient, not durable, over the study period ^[12]. That word "transiently" is doing real work in that paper's own conclusion; it is not a claim of a lasting cure, and it is one rat study, not a human trial. If you're weighing ghk cu peptides injections against a topical serum, understand you are choosing between two evidence bases that barely overlap. Injectable use in the U.S. for cosmetic or orthopaedic purposes generally happens through compounding pharmacies operating under state pharmacy law and federal compounding rules, not through an FDA-approved drug product; there is no GHK-Cu product listed as an approved drug in the FDA's Drugs@FDA database ^[13].

Is GHK-Cu FDA approved, and is it legal to buy?

No GHK-Cu product is FDA-approved as a drug. Searching Drugs@FDA, the FDA's official database of approved drug products, returns nothing for GHK-Cu ^[13]. That means every injectable GHK-Cu product on the market in the U.S. is either a compounded preparation or sold outside the regulated drug supply chain, and every topical GHK-Cu product is marketed as a cosmetic ingredient, not a drug. Compounding pharmacies can legally prepare drugs from bulk substances under section 503A of the Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 353a, but only using substances that meet specific criteria, including appearing on FDA's approved bulks list or otherwise qualifying ^[14]. FDA maintains that list at 21 CFR 216.23 for 503A compounding ^[15] and 21 CFR 216.24 for 503B outsourcing facilities ^[16]. As of this writing, GHK-Cu is not on either finalized bulks list; FDA's public materials on bulk drug substances nominated for compounding show ongoing review of many peptides, GHK-Cu included in various nomination cycles, without final placement on the approved list ^[17][18]. Practically, that means the regulatory status of injectable GHK-Cu sits in a gray zone: not banned outright, but not affirmatively approved for compounding either, which is a meaningfully different legal position than an FDA-approved drug. This is exactly the kind of detail worth checking against ghk-cu side effects and sourcing guidance before anyone assumes a compounded product carries the same oversight as a pharmacy-filled prescription for an approved drug.

What does GHK-Cu do for wound healing, fibrosis, and inflammation beyond skin?

The animal literature extends well past cosmetic skin use into organ-level inflammation and fibrosis models, and this is genuinely one of the more interesting threads in the GHK-Cu record. In a bleomycin-induced pulmonary fibrosis model in mice, GHK-Cu reduced markers of oxidative stress and inflammation, according to a 2020 study in Life Sciences ^[19]. A 2024 Redox Biology study found that a GHK-Cu tripeptide complex reduced lung inflammation and fibrosis in a silicosis model by acting on a protein called peroxiredoxin 6 ^[20]. Earlier, a 2016 Oncotarget study reported that GHK-Cu improved outcomes in a lipopolysaccharide-induced acute lung injury model in mice ^[21]. Outside the lungs, a 2025 Frontiers in Pharmacology study found beneficial effects of GHK-Cu in an experimental colitis model, and proposed underlying mechanisms for that effect ^[22]. A 2023 study in the Journal of Cachexia, Sarcopenia and Muscle found that GHK-Cu rescued skeletal muscle dysfunction caused by cigarette smoke exposure in an animal model, acting through a pathway involving the protein sirtuin 1 ^[23]. These are all disease-model animal studies, not human trials, and none of them are about skin appearance. They matter here because they show the antioxidant and anti-inflammatory mechanism isn't a cosmetic-marketing invention; it's a real, repeatedly-studied biological activity of the copper-peptide complex across very different tissue types. Whether any of that translates into an approved human therapy is still an open question.

Does GHK-Cu help with hair, acne, or bone and joint healing?

Hair: the direct human hair-growth trial record for GHK-Cu specifically is thin in this source set; most of the hair-related interest in copper peptides traces back to older industry-funded work rather than the newer academic literature reviewed here, so treat hair claims with real skepticism until you find a specific controlled trial. Acne: GHK-Cu's antioxidant and tissue-remodeling properties are sometimes extrapolated into acne scarring or post-inflammatory marks, largely riding on the collagen-signaling data from skin studies ^[6][24] rather than acne-specific trials. If you're specifically weighing this use, does ghk cu help with acne is worth reading before buying anything marketed that way. Bone and joint: a 2025 Bioconjugate Chemistry paper describes copper complexes built from new GHK-hyaluronan conjugates showing antioxidant properties along with what the authors call synergistic osteogenic (bone-forming) and angiogenic (blood-vessel-forming) effects in lab models ^[24]. A 2026 Journal of Controlled Release study describes a Golgi-targeted copper delivery strategy aimed at fascia regeneration, working by boosting the activity of copper-dependent enzymes ^[25]. These are early-stage materials-science and cell-biology papers, worth watching, not yet a basis for a treatment claim. The 2015 rat ACL study mentioned earlier remains the closest thing to a joint-specific in-vivo test, and its own result was a transient benefit, not a durable one ^[12].

How strong is the human clinical trial evidence, honestly?

Thinner than the total volume of papers suggests. GHK-Cu has an unusually large body of cell-culture work, animal disease models, and formulation chemistry (liposome encapsulation, biosensors, hydrogels, nanochannel copper detection) because it's a chemically convenient, biologically active molecule that's easy to study in a lab. That is not the same thing as a deep bench of randomized controlled human trials. A 2020 review in Aging Pathobiology and Therapeutics on GHK's potential as an anti-aging peptide surveys this landscape and is explicit that much of the anti-aging case rests on mechanistic and preclinical data rather than large human outcome trials ^[26]. A 2026 review in the International Journal of Molecular Sciences covering therapeutic peptides in aesthetic, metabolic, and endocrine conditions places GHK-Cu within a broader category of peptides where clinical evidence, safety data, and regulatory clarity are all still catching up to lab-level interest ^[27]. For a musculoskeletal-specific version of the same caution, a 2026 Sports Medicine review on the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance draws a hard line between peptides with real approved-drug status and the much larger group, GHK-Cu included, being used off-label or through compounding without controlled trial support ^[28]. That review is a genuinely useful gut check before anyone spends real money on an injectable peptide protocol sold on forum enthusiasm rather than trial data.

Is GHK-Cu safe, and what should I know about copper accumulation?

Copper is an essential mineral, but it is not automatically safe just because the body needs some. Copper accumulates in the liver in Wilson disease and in other overload states, and excess copper drives oxidative damage through the same free-radical chemistry that, at controlled doses, is part of what makes GHK-Cu biologically active in the first place. The dose and the route both matter enormously here. Topical use puts a small, largely surface-limited copper load onto skin, and the limited penetration described earlier ^[7][8] arguably works in the user's favor from a safety standpoint, even though it may reduce efficacy. Injectable use bypasses that barrier and delivers copper directly into tissue and potentially into circulation, which is a different risk calculus entirely and one none of the review papers here treat lightly ^[10][28]. Realistic, non-alarmist concerns to actually think about: total copper load if using multiple products or injections concurrently, interactions with any condition or medication affecting copper metabolism, product purity and contamination risk in unregulated compounded or gray-market injectables, and simple irritation or sensitization at injection or application sites. None of the papers in this review set report a large human safety trial establishing a clear safe dose range for chronic injectable GHK-Cu use, which is itself the honest answer: nobody has published that data yet, at least not in this literature. For anyone actually using it, ghk-cu side effects and appropriate ghk cu dosage guidance from a provider matter more than any serum's marketing copy.

How should I think about dosing, and does more copper mean better results?

There is no established, trial-validated "optimal dose" for GHK-Cu in this literature, topical or injectable, and anyone quoting a precise number as clinically proven is overstating what's known. Cell-culture and animal studies use concentrations chosen for those specific models, and those numbers do not directly translate to a human topical percentage or an injectable milligram dose. For topical products, concentration is only half the story; delivery technology (plain aqueous solution versus liposomal encapsulation) changes how much of a given concentration actually reaches active skin layers ^[7][8][9]. A higher percentage on the label does not guarantee more peptide getting where it needs to go, and it does mean more copper sitting on skin, which is not obviously better. For injectable use, dosing decisions sit with the prescribing provider and compounding pharmacy, working from whatever limited human and animal data exists rather than from an FDA-approved label, since none exists ^[13]. That is a meaningfully different situation than dosing an approved drug, and it's worth reading ghk cu dosage with that gap in mind rather than assuming injectable protocols are as standardized as they sound online.

What should I actually look for before buying a GHK-Cu product?

Start with the route. Decide honestly whether you want a topical cosmetic product or are considering an injectable, because the evidence bases, oversight, and risks genuinely diverge, as covered above. For topical products, look for stated delivery technology (liposomal encapsulation has actual published support ^[8][9]), a listed concentration, and manufacturing transparency. A product that just says "contains copper peptides" with no other detail is selling you the ingredient's reputation, not demonstrated performance. For injectable use, the relevant question is not the peptide's cell-culture data, it's who is dispensing it and under what oversight. Compounded injectable GHK-Cu should come through a licensed pharmacy operating under a provider's evaluation, not a direct-to-consumer gray-market seller. Copper Peptide Direct's own editorial position is straightforward on this: we don't compound or manufacture anything ourselves, and readers considering an injectable route should look at buy ghkcu for the provider-reviewed sourcing path and the specific fulfilling pharmacy partner named there, rather than assume any online seller offers equivalent oversight. Whatever the route, ask to see, or ask your provider to explain, exactly which studies support the specific use you're considering. If someone can't tell you whether a claim comes from a mouse burn-wound study ^[2], a fibroblast dish ^[6], or an actual human trial, that's your answer about how solid the claim is.

What does before-and-after evidence for GHK-Cu actually look like?

Photographic before-and-after images circulating online for injectable GHK-Cu are almost never tied to a published, peer-reviewed trial with a defined protocol, timeline, and control group; they are individual, unverified, and impossible to generalize from. That doesn't mean nothing is happening in those cases, it means there's no way to know from a photo alone what dose, formulation, or concurrent treatment produced the result. The controlled data that does exist is what's summarized through this article: animal wound and burn models ^[2][3], ex-vivo and fibroblast collagen studies ^[6], and mechanistic reviews ^[1][26]. If you want the fuller picture of what realistic outcomes and timelines look like, and how to read injectable before-and-after claims with appropriate skepticism, see ghk-cu peptide injection before and after.

GHK-Cu research at a glance

Frequently asked questions

What is GHK-Cu used for?

GHK-Cu (glycyl-L-histidyl-L-lysine-copper) is studied for wound healing, skin collagen signaling, and antioxidant/anti-inflammatory effects in animal and cell models, plus early orthopaedic and lung-fibrosis research. Topical cosmetic use targets wrinkles and skin texture; injectable use is explored off-label for musculoskeletal and anti-aging purposes, though controlled human trial data for injectable use is very limited ^[10][28].

Is GHK-Cu the same as copper peptides in general?

GHK-Cu is the specific, most-studied copper peptide, but "copper peptides" is a broader category term used in cosmetics. When a product just says "copper peptides" without naming GHK-Cu specifically, you can't assume it's referencing this particular literature; check the ingredient list for the specific tripeptide-copper complex named.

Does topical GHK-Cu actually penetrate the skin?

Penetration is a real formulation challenge because GHK-Cu is water-soluble and charged. A 2025 Molecules study questioned whether current methods can even reliably measure GHK-Cu skin permeation from liposomal formulations ^[7], and separate 2023-2024 studies focus specifically on liposomal encapsulation as a strategy to improve delivery ^[8][9]. Plain aqueous serums face a bigger penetration barrier than encapsulated formulations.

Is injectable GHK-Cu FDA approved?

No. Drugs@FDA, the FDA's approved drug products database, lists no GHK-Cu product ^[13]. Injectable GHK-Cu is generally obtained through compounding pharmacies, and GHK-Cu is not confirmed on the finalized 503A or 503B bulk drug substance lists at 21 CFR 216.23 and 216.24 ^[15][16], which puts its compounding status in a regulatory gray zone rather than a clearly approved one.

What's the difference between topical and injectable GHK-Cu?

Topical GHK-Cu is a cosmetic-route product limited mostly to skin surface and upper dermal effects, constrained by penetration through the skin barrier ^[7][8]. Injectable GHK-Cu bypasses that barrier entirely, delivering the compound directly into tissue with different absorption and risk profiles. Clinical reviews treat these as distinct categories with separate evidence bases, not interchangeable products ^[10].

Can GHK-Cu help with hair growth?

The peer-reviewed literature reviewed here doesn't include a dedicated controlled human hair-growth trial for GHK-Cu specifically; most hair-related claims trace to older industry-associated work rather than the newer academic studies on wound healing and skin collagen. Treat hair-growth claims for GHK-Cu with more skepticism than the wound-healing and skin-collagen claims, which have stronger animal and ex-vivo support.

Does GHK-Cu help with acne or acne scarring?

There's no acne-specific controlled trial in this literature. Claims usually extrapolate from GHK-Cu's collagen-signaling and antioxidant effects in skin cell and ex-vivo studies ^[6][24], not from trials measuring actual acne lesions or scarring outcomes. See does ghk cu help with acne for a fuller breakdown before assuming this use case is well-supported.

Is copper accumulation a real risk with GHK-Cu use?

Copper is essential but not benign in excess; conditions like Wilson disease show what chronic copper overload can do to the liver and other organs. Topical use likely poses lower systemic risk given limited skin penetration ^[7][8], while injectable use delivers copper more directly into tissue. No paper in this literature establishes a proven safe long-term dose range for chronic use, injectable or topical.

What does the animal research say about GHK-Cu and wound healing?

A 2017 mouse study found GHK-Cu liposomes sped scald wound healing via more cell proliferation and new blood vessel growth ^[2]. A 2025 hydrogel study found improved healing in infected wound models ^[3]. These are animal models, which show real biological activity but don't guarantee identical results in human clinical wound care.

How does GHK-Cu affect joints, fascia, or bone in the research?

A 2015 rat ACL reconstruction study found GHK-Cu(II) produced a healing benefit the authors described as transient, not durable ^[12]. Newer 2025-2026 papers describe osteogenic and angiogenic effects in cell/materials models ^[24] and a Golgi-targeted copper delivery approach for fascia regeneration ^[25]. All of this is preclinical; no human joint-outcome trial exists in this record.

Are there human clinical trials proving GHK-Cu reduces wrinkles?

The human evidence is smaller-scale than the total publication volume suggests. Reviews describe topical GHK as having advantages and unresolved formulation problems ^[5], and specific fibroblast/ex-vivo work shows collagen IV upregulation ^[6], but large randomized controlled wrinkle-outcome trials in living human volunteers are not well represented in this literature.

Where can I buy GHK-Cu safely?

For topical products, look for stated delivery technology and transparent concentration labeling. For injectable GHK-Cu, use a provider-reviewed path through a licensed compounding pharmacy rather than an unregulated seller; see buy ghkcu for the provider-reviewed sourcing route and the specific fulfilling pharmacy named there.

What's a realistic GHK-Cu dosage?

No trial in this literature establishes a validated optimal human dose, topical or injectable. Topical concentration alone doesn't determine effect since delivery technology changes how much reaches active skin layers ^[7][8][9]. Injectable dosing should come from a provider working from limited available data, not a standardized approved label, since none exists ^[13]. See ghk cu dosage for more detail.

Sources

1. International Journal of Molecular Sciences, 2018 (PMID 29986520): GHK-Cu influences gene networks tied to tissue repair, oxidative stress protection, and inflammation control
2. Wound Repair and Regeneration, 2017 (PMID 28370978): GHK-Cu liposomes accelerated scald wound healing in mice via increased cell proliferation and angiogenesis
3. Biomaterials Research, 2025 (PMID 39902373): A food-derived tripeptide-copper self-healing hydrogel improved healing in infected wound models
4. Colloids and Surfaces B: Biointerfaces, 2025 (PMID 40716276): An injectable hydroxyapatite microsphere filler loaded with GHK-Cu showed anti-inflammatory and antioxidant effects
5. BioImpacts, 2025 (PMID 39963574): Review of topically applied GHK as an anti-wrinkle peptide covering advantages and formulation problems
6. Journal of Cosmetic Dermatology, 2023 (PMID 37062921): GHK-Cu combined with hyaluronic acid upregulated collagen IV in fibroblast and ex-vivo skin tests
7. Molecules, 2025 (PMID 39795193): Study questions whether current methods can reliably measure GHK-Cu skin permeation from liposomal formulations
8. Pharmaceutics, 2023 (PMID 37896245): Liposomal encapsulation is studied as a carrier strategy for GHK-Cu in cosmetic applications
9. Electrophoresis, 2024 (PMID 39451062): CE-ICP-MS/MS methods used to monitor GHK-Cu encapsulation levels in liposomal cosmetic formulations
10. The American Journal of Sports Medicine, 2026 (PMID 41476424): Primer treats injectable peptide therapy as a distinct clinical category with its own risk and evidence considerations for orthopaedic/sports medicine physicians
11. JAAOS Global Research & Reviews, 2026 (PMID 41490200): Review covers therapeutic peptides in orthopaedics including regulatory and practical challenges of compounded injectable peptides
12. Journal of Orthopaedic Research, 2015 (PMID 25731775): GHK-Cu(II) complex transiently improved healing outcome in a rat model of ACL reconstruction
13. FDA, Drugs@FDA approved drug products database: No GHK-Cu product is listed as an FDA-approved drug
14. 21 U.S.C. 353a, pharmacy compounding: Compounding pharmacies may prepare drugs from bulk substances under section 503A subject to specific statutory criteria
15. 21 CFR 216.23, the final 503A Bulks List: FDA's finalized list of bulk drug substances approved for 503A compounding does not include GHK-Cu
16. 21 CFR 216.24, the 503B Bulks List: FDA's finalized list of bulk drug substances for 503B outsourcing facility compounding does not include GHK-Cu
17. FDA, bulk drug substances used in compounding under section 503A: FDA's compounding bulk substance program shows ongoing review status for many nominated peptides
18. FDA, bulk drug substances nominated for use in compounding (current list): Current FDA nomination list reflects substances under review rather than finalized approval for compounding
19. Life Sciences, 2020 (PMID 31809714): GHK-Cu reduced oxidative stress and inflammation markers in a bleomycin-induced pulmonary fibrosis mouse model
20. Redox Biology, 2024 (PMID 38879894): GHK-Cu tripeptide complex reduced lung inflammation and fibrosis in a silicosis model via peroxiredoxin 6
21. Oncotarget, 2016 (PMID 27517151): GHK-Cu improved outcomes in a lipopolysaccharide-induced acute lung injury mouse model
22. Frontiers in Pharmacology, 2025 (PMID 40672369): GHK-Cu showed beneficial effects in an experimental colitis model with proposed underlying mechanisms
23. Journal of Cachexia, Sarcopenia and Muscle, 2023 (PMID 36905132): GHK-Cu rescued cigarette smoke-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway in an animal model
24. Bioconjugate Chemistry, 2025 (PMID 40123442): Copper complexes with new GHK-hyaluronan conjugates showed antioxidant properties and synergistic osteogenic and angiogenic effects in lab models
25. Journal of Controlled Release, 2026 (PMID 41371501): A Golgi-targeted copper delivery strategy aimed at fascia regeneration works by boosting copper-dependent enzyme activity
26. Aging Pathobiology and Therapeutics, 2020 (PMID 35083444): Review of GHK's potential as an anti-aging peptide notes reliance on mechanistic and preclinical data over large human trials
27. International Journal of Molecular Sciences, 2026 (PMID 42123471): Review of therapeutic peptides in aesthetic, metabolic, and endocrine conditions notes clinical evidence and regulatory clarity still catching up to lab interest
28. Sports Medicine (Auckland, N.Z.), 2026 (PMID 41966639): Review distinguishes approved peptide therapies from the larger group of unapproved/compounded peptides, GHK-Cu included, lacking controlled trial support for musculoskeletal use